PROCEPT BioRobotics to Report Third Quarter 2022 Financial Results on November 3, 2022

REDWOOD CITY, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022. The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com

Staff

Recent Posts

PLHM Expands Presence in Alberta with Acquisition of a Clinic in Fort Saskatchewan and an Additional Virtual Presence Across Canada

Calgary, Alberta--(Newsfile Corp. - April 4, 2024) - PLHM, a leading healthcare solutions provider, is…

1 hour ago

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a…

2 hours ago

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale…

2 hours ago

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical ScenariosLATHAM, N.Y.--(BUSINESS…

2 hours ago

Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

The leading benefits solution and largest infertility advocacy non-profit will host a series of events…

2 hours ago